Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358358 · ClinicalTrials.gov registry record · Phase 4
Chronic Obstructive Pulmonary Disease Endpoints Study
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
NCT00358358: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00358358 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 163 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00358358, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
Study Summary
This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.
Interventions
- DRUG Fluticasone Propionate/Salmeterol 500/50mcg combination
- DRUG Fluticasone Propionate 500mcg
- DRUG Salmeterol 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
What the finished NCT00358358 record still lists
NCT00358358 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 3 interventions - of which Fluticasone Propionate/Salmeterol 500/50mcg combination is the first listed.
NCT00358358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00358358 about?
NCT00358358 is a clinical study titled "Chronic Obstructive Pulmonary Disease Endpoints Study". This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathless...
What is the current status of trial NCT00358358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2006-03. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00358358?
The interventions under investigation include: Fluticasone Propionate/Salmeterol 500/50mcg combination (DRUG), Fluticasone Propionate 500mcg (DRUG), Salmeterol 50mcg (DRUG).
Who is sponsoring clinical trial NCT00358358?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00358358's enrollment target sits among peer trials
163 501st of 2000 higher than 1,498 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia